Statements (61)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:vaccine
|
gptkbp:administered_by |
gptkb:children
intramuscular injection |
gptkbp:age_group |
4-6 years
6 months 2 months 4 months 15-18 months |
gptkbp:associated_with |
Herd immunity
|
gptkbp:available_in |
liquid form
pre-filled syringes |
gptkbp:booster_recommended |
every 10 years
|
gptkbp:clinical_trial |
conducted prior to approval
|
gptkbp:community_health |
reduces incidence of diseases
|
gptkbp:contains |
inactivated toxins
|
gptkbp:contraindication |
severe allergic reaction
progressive neurological disorder |
gptkbp:developed_by |
gptkb:Sanofi_Pasteur
|
gptkbp:first_introduced |
gptkb:1991
|
https://www.w3.org/2000/01/rdf-schema#label |
DTa P vaccine
|
gptkbp:immunity_duration |
approximately 5-10 years
|
gptkbp:is_recommended_by |
gptkb:CDC
gptkb:WHO |
gptkbp:is_vulnerable_to |
varies by provider
inactivated vaccine part of routine immunization programs important for public awareness available in pharmacies ongoing studies for new formulations available in hospitals available in clinics updated periodically by health authorities 3 doses in infancy booster dose in adolescence booster dose in adulthood booster dose in early childhood conducted to monitor safety and effectiveness high efficacy against diseases significantly reduced disease rates |
gptkbp:part_of |
childhood immunization schedule
|
gptkbp:produced_by |
multiple manufacturers
|
gptkbp:replaces |
DTP vaccine
|
gptkbp:safety_features |
generally safe
|
gptkbp:serves |
gptkb:diphtheria
tetanus pertussis |
gptkbp:side_effect |
fever
irritability drowsiness loss of appetite local reaction at injection site monitored post-licensure |
gptkbp:storage |
refrigerated
|
gptkbp:type |
combination vaccine
|
gptkbp:vaccine_funding |
often covered by insurance
|
gptkbp:vaccine_policy |
mandated in many states
|
gptkbp:bfsParent |
gptkb:diphtheria
gptkb:diphtheria_toxoid gptkb:tetanus_toxoid gptkb:diphtheria-tetanus-pertussis_vaccine |
gptkbp:bfsLayer |
6
|